IGF::OT::IGF - CORE INFRASTRUCTURE SUPPORT

IGF::OT::IGF - 核心基础设施支持

• 批准号: 9553428
• 负责人: HOWARD BAILEY
• 金额: $ 81.62万
• 依托单位: UNIVERSITY OF WISCONSIN-MADISON
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-09-24 至 2018-09-23
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9553428
• 关键词: Clinical; Clinical Chemoprevention; Clinical Trials; Conduct Clinical Trials; Contractor; Data; Development; Division of Cancer Prevention; Drug Industry; Funding; Guidelines; Individual; Maintenance; Malignant Neoplasms; Molecular Target; Monitor; National Cancer Institute; Outcome; Performance; Phase; Prevention; Preventive; Protocols documentation; Request for Proposals; Research Infrastructure; Safety; Site; Specific qualifier value; Time; Visit; cancer prevention; clinically relevant; data management; interest; laboratory experiment; meetings; prevention clinical trial; programs; protocol development

The National Cancer Institute (NCI), Division of Cancer Prevention (DCP) Phase 0/I/II Cancer Prevention Clinical Trials Program supports early clinical trials to rapidly evaluate the clinical activity and biologic effects of cancer preventive agents of interest to DCP. The agents to be studied shall include agents developed by the pharmaceutical industry and provided to DCP for collaborative development, commercially available agents, and agents developed by DCP. The objectives of this Task Order are to provide the core infrastructure to support the conduct of the clinical trials.

美国国家癌症研究所(NCI)癌症预防部门(DCP)0/I/II期癌症预防临床试验计划支持早期临床试验，以快速评估DCP感兴趣的癌症预防药物的临床活性和生物效果。拟研究的药剂应包括制药行业开发并提供给DCP用于协作开发的药剂、商业上可用的药剂和DCP开发的药剂。本任务单的目标是提供核心基础设施，以支持临床试验的进行。